Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHMT1 | P34896 | 10/20 | 0.47 |
| ▸ | SHMT2 | P34897 | 8/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | EIF4E | P06730 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | CRHBP | P24387 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 2/20 | 0.38 |
| ▸ | CNR2 | P34972 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1338217 | 0.91 | SHMT1 (0.40) | SHMT1SHMT2KDM4EEIF4ESMN1; SMN2 | |
| SCHEMBL1338957 | 0.90 | GFER (0.44) | SHMT1SHMT2KDM4EALDH1A1HPGD | |
| SCHEMBL1336852 | 0.90 | SHMT1 (0.38) | SHMT1SHMT2KDM4EALDH1A1HPGD | |
| SCHEMBL1338195 | 0.88 | SHMT1 (0.37) | SHMT1SHMT2KDM4EALDH1A1HPGD | |
| SCHEMBL1338262 | 0.86 | ENPP2 (0.46) | — | |
| SCHEMBL1338722 | 0.86 | GABRA1 (0.42) | SHMT1SHMT2KDM4EALDH1A1HPGD | |
| SCHEMBL1339227 | 0.86 | GABRA1 (0.41) | KDM4EALDH1A1HPGDGAAEIF4E | |
| SCHEMBL1339278 | 0.85 | SHMT1 (0.45) | SHMT1SHMT2KDM4EEIF4ESMN1; SMN2 | |
| SCHEMBL1338076 | 0.85 | CNR1 (0.40) | KDM4EALDH1A1HPGDGAAEIF4E | |
| SCHEMBL1338811 | 0.84 | RAB9A (0.43) | KDM4EGAAEIF4ESMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063061-B2 | 6-(2-amino-1,3-thiazol-4-yl)-3-(2,4-dichlorophenyl)-1-methyl-1,9-dihydro-2H-pyrido[2,3-b]indol-2-one; affinity for GABAA-receptor-associated omega modulatory sites | SANOFI-AVENTIS (FR) | 2011-11-22 | — | — | US | disclosed |
| EP-1940840-B1 | 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI AVENTIS (FR) | 2010-07-21 | — | — | EP | disclosed |
| US-20080262020-A1 | 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof | SANOFI-AVENTIS (FR) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262020-A1 | 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof | CYP11B2, CYP11B1, CYP2D6 | SHMT1 1498/4885SHMT2 467/4885KDM4E 1908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.